Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis
Mohamed Attauabi, Gorm Roager Madsen, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch
Topics & Concepts
VedolizumabMedicineUlcerative colitisCrohn's diseaseMeta-analysisInternal medicineGastroenterologyDiseaseInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesMicroscopic Colitis